Updates on company’s negotiable securities for investors’ information

Announcement on change of accountant due to internal adjustment of accounting firm
March 13, 2020
Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.
April 6, 2020

1.Date of occurrence of the event: Mar 23, 2020
2.Cause of occurrence: Notified by Taipei Exchange (TPEx) to release information
3.Financial and business information:

(1 ) Latest 1 month

SUBJECT                                                         FEB 2020        FEB 2019       %CHANGE
_________________________________________________________________________________
OPERATING REVENUE (MILLION)                   0.00                 0.00                 N/A
NET LOSS BEFORE TAX (MILLION)            -157.99              -65.17             -142.43
NET LOSS AFTER TAX (MILLION)               -157.38              -64.73             -143.13
LOSS PER SHARE (DOLLAR)                           -0.84                -0.36              -133.33

(2) Latest 2 months, accumulated
SUBJECT                                                     JAN-FEB 2020     JAN- FEB 2019       %CHANGE
______________________________________________________________________________________
OPERATING REVENUE (MILLION)                 0.00                      0.00                       N/A
NET LOSS BEFORE TAX (MILLION)          -183.34                 -100.27                    -82.85
NET LOSS AFTER TAX (MILLION)             -182.63                   -99.60                    -83.36
LOSS PER SHARE (DOLLAR)                         -0.97                     -0.56                     -73.21

(3) Latest quarter
SUBJECT                                                      Q4 2019            Q4 2018              %CHANG
___________________________________________________________________________________
OPERATING REVENUE (MILLION)               0.31                   0.28                     10.71
NET LOSS BEFORE TAX (MILLION)        -520.90             -409.00                    -27.36
NET LOSS AFTER TAX (MILLION)           -519.66             -407.40                    -27.56
LOSS PER SHARE (DOLLAR)                       -2.75                 -2.33                     -18.03

(4) Latest 4 quarters, accumulated
SUBJECT                                                       Q1-Q4 2019
______________________________________________________
OPERATING REVENUE (MILLION)                     0.87
NET LOSS BEFORE TAX (MILLION)           -1,445.18
NET LOSS AFTER TAX (MILLION)              -1,439.59
LOSS PER SHARE (DOLLAR)                             -7.76

NOTE:
<1>Above financial statement for Jan and Feb 2020 and the same period of last year were calculated by IFRS, without accountant audition. Only for investors’ reference.
<2>Financial statements of latest quarter, Q4 2019, was for the single quarter not accumulated, which is calculated by IFRS, without accountant audition. Only for investors’ reference.
<3>Financial statements of latest 4 quarters, Q1 to Q4 2019, were calculated by IFRS, without accountant audition. Only for investors’ reference.

4.Any material information that needs to be specified according to Article 4 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: None
5.Any material information in a press conference listed under Article 11 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: None
6.Any other matters that need to be specified:Company is under normal operation and financial status. By end of February 2020, company owns total capital of NTD 4.2 billion, which is enough to support all research and operation costs.